NewGenIvf Group (NASDAQ:NIVF) & Oncology Institute (NASDAQ:TOI) Head-To-Head Survey

A comparative analysis of small-cap medical companies NewGenIvf Group (NIVF) and Oncology Institute (TOI) suggests TOI is the more favorable investment. While NIVF exhibits higher institutional ownership and less negative earnings despite significantly lower revenue ($5.43M vs $393.41M), Oncology Institute outperforms on 7 of 13 comparative factors. This includes a stronger consensus analyst rating and a projected 76.32% potential upside, leading analysts to view Oncology Institute as more promising.

Analysis

The comparative analysis between small-cap medical companies NewGenIvf Group (NIVF) and Oncology Institute (TOI) indicates a preference for TOI among analysts. Oncology Institute outperforms NewGenIvf Group on 7 of 13 comparative factors, including a stronger consensus analyst rating of 2.75 versus NIVF's 1.00. This leads to a projected potential upside of 76.32% for TOI, based on a $7.00 price target.

NewGenIvf Group exhibits significantly higher institutional ownership at 66.2% and insider ownership at 31.8%, compared to Oncology Institute's 36.9% and 8.5% respectively. Both companies demonstrate low volatility relative to the S&P 500, with NIVF having a beta of -0.12 and TOI a beta of 0.07.

Financially, Oncology Institute reports substantially higher gross revenue of $393.41 million against NewGenIvf Group's $5.43 million, yet incurs a much larger net loss of $64.66 million compared to NIVF's -$0.52 million. Despite higher revenue, TOI's profitability metrics are significantly negative, with a net margin of -13.21%, return on equity of -1,527.21%, and return on assets of -35.20%.

Key Decisions for Investors

• Consider Oncology Institute (TOI) for its strong analyst consensus and significant projected upside, while carefully weighing its substantial current unprofitability despite higher revenue.
• Evaluate NewGenIvf Group (NIVF) for its higher institutional and insider ownership, which may signal long-term confidence, alongside its comparatively better earnings performance despite much lower revenue.
• Monitor both companies' progress towards profitability and sustainable revenue growth, as both operate with negative net incomes, and assess their low beta values in the context of overall portfolio risk management.